Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund posted a return of -4.87% gross of fees compared to -3.60% return for the Russell 1000 Growth Index. Holdings in Information Technology, Consumer Discretionary, and Materials were the major performance detractors. At the same time, investments in Consumer Staples and Financials and an overweight position in Health Care contributed positively to the strategy’s performance in the quarter. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.
Aristotle Atlantic highlighted stocks like Bio-Techne Corporation (NASDAQ:TECH) in its Q3 2022 investor letter. Headquartered in Minneapolis, Minnesota, Bio-Techne Corporation (NASDAQ:TECH) is a developer and manufacturer of regent solutions, instruments, and services for research and clinical diagnostic markets. On November 23, 2022, Bio-Techne Corporation (NASDAQ:TECH) stock closed at $336.32 per share. One-month return of Bio-Techne Corporation (NASDAQ:TECH) was 13.71% and its shares lost 29.49% of their value over the last 52 weeks. Bio-Techne Corporation (NASDAQ:TECH) has a market capitalization of $13.198 billion.
Aristotle Atlantic made the following comment about Bio-Techne Corporation (NASDAQ:TECH) in its Q3 2022 investor letter:
“Bio-Techne Corporation (NASDAQ:TECH) shares were weak in the third quarter. The company reported results in line with consensus with 14% organic revenue growth. We believe part of the decline is attributable to the rise in U.S. Treasury yields, which tends to have an outsized negative impact on high-valuation growth stocks. Bio-Techne continues to execute on the diverse aspects of its growth plans. We believe that Bio-Techne continues to be in an enviable position of manufacturing high performance research and diagnostic tools and supplies to the biopharmaceutical industry.”
goodluz/Shutterstock.com
Bio-Techne Corporation (NASDAQ:TECH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 32 hedge fund portfolios held Bio-Techne Corporation (NASDAQ:TECH) at the end of the third quarter, which was 31 in the previous quarter.
We discussed Bio-Techne Corporation (NASDAQ:TECH) in another article and shared Baron Fund’s views on the company. In addition, please check out our hedge fund investor letters Q3 2022 page for more investor letters from hedge funds and other leading investors.
Suggested Articles:
- 15 Largest Education Companies in the World
- 12 Best Robotics Stocks To Buy According to Hedge Funds
- 12 Best High Yield Dividend Stocks To Buy
Disclosure: None. This article is originally published at Insider Monkey.
